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Abstract
Background: N-acetylcysteine is used to treat acetaminophen toxicity and is available in both intravenous and oral
formulations. Our report describes a patient treated with intravenous N-acetylcysteine for acetaminophen toxicity
who died after an anaphylactoid reaction following initiation of the infusion.
Objective: Clinicians should be aware of potential complications when deciding on which formulation of N-
acetylcysteine to administer.
Case Report: A 53-year-old male presented with altered mental status after an overdose of acetaminophen/
hydrocodone and carisoprodol. He had an acetaminophen level of 49 mcg/ml with an unknown time of ingestion.
The patient was admitted to the intensive care unit (ICU) on a naloxone drip and was started on intravenous N-
acetylcysteine (NAC) at the presumed dose of 150 mg/kg. Shortly after initiating the NAC infusion, the patient
developed periorbital edema, skin rash, and hypotension. The infusion of N-acetylcysteine was immediately
stopped and the patient required emergent intubation. Resuscitation was begun with intravenous fluids followed
by the initiation of phenylephrine. He developed ST elevation in the inferior leads on his ECG. This evolved into an
inferior myocardial infarction by ECG and cardiac enzymes. Echocardiogram showed global, severe hypokinesis with
an ejection fraction of less than 20% in a patient with no pre-existing cardiac history. Despite aggressive support,
he died approximately 17 hours after the initiation of intravenous NAC. Further investigation found a 10-fold
formulation error in his NAC loading dose.
Conclusion: The intravenous formulation of NAC has a higher probability of significant adverse effects and
complications not described with the oral formulation. Clinicians should be aware of these potential complications
when deciding on which formulation to administer.
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Introduction
Acetaminophen is one of the most commonly used over-
the-counter (OTC) analgesics and one of the most com-
mon causes of poisoning worldwide. Additionally, it is
used in combination with both prescription narcotics and
OTC medications, making it one of the most accessible
medications for potential ingestions. Annually, poison
centers receive more than 93,000 calls regarding acetami-
nophen exposures [1]. Fortunately, antidotal therapy is
available for acetaminophen toxicity in the form of
N-acetylcysteine (NAC).
The benefits and efficacy of early administration of NAC
for acetaminophen toxicity are well described [2]. NAC is
thought to have four basic mechanisms of action to limit
acetaminophen toxicity: It replenishes endogenous glu-
tathione, directly converts the acetaminophen metabolite
N-acetyl-p-benzoquinonimine (NAPQI) to a non-toxic
metabolite, facilitates increased formation of N-acetyl-p-
aminophenol-sulfate, and buffers cellular damage from
NAPQI by acting as a reducing agent [2]. Regardless of
the route of administration, there has not been a reported
treatment failure for an acute acetaminophen only inges-
tion, as predicted by the Rumack-Matthew nomogram,
when NAC was given within 8 h of ingestion.
Prior to 2004, the only Food and Drug Administration
(FDA) approved formulation available in the US was the
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provided the original work is properly cited.oral form, despite widespread use of the intravenous for-
mulation in Europe, Australia, and Canada [3]. With the
introduction of the approved intravenous formulation,
adverse reactions have become an increasing concern
with a well-described anaphylactoid reaction leading to
a delay in administration or other more serious compli-
cations. In this report, we present a case with an ana-
phylactoid reaction immediately after intravenous
administration of a ten-fold formulation error of NAC
associated with a massive myocardial ischemia and
death.
Case report
A 53-year-old male with chronic obstructive pulmonary
disease, hepatitis C, alcohol abuse, and chronic back pain
presented with altered mental status after a presumed sui-
cide attempt after estrangement from his girlfriend. The
patient did not have any known cardiovascular history.
Family became concerned after the patient failed to wake
up, and 911 was called. The patient was found to be stu-
porous with pinpoint pupils. An intravenous line was
established, and after administration of naloxone the
patient became belligerent. After discussion with family
and review of his medications, it was determined that the
patient likely overdosed on an acetaminophen/hydroco-
done product and carisoprodol. He was admitted to the
ICU requiring a naloxone drip (0.5 mg/h). He had an acet-
aminophen level of 49 mcg/ml with an unknown time of
ingestion. His transaminase levels and coagulation factors
were within normal limits (AST 32 IU/l, ALT 47, and INR
0.97). Because of the detectable acetaminophen level with
an unknown time on ingestion, intravenous NAC at
150 mg/kg (84 kg-12,600 mg NAC) was ordered.
Immediately after initiation of the intravenous NAC,
which was to be infused over 1 h, the patient developed
periorbital edema, rash, and hypotension with a systolic
blood pressure of 80 mmHg. The infusion was stopped.
He was rapidly intubated without medications, and resus-
citation was initiated with intravenous normal saline.
Hypotension persisted despite fluid resuscitation with 2 l
normal saline, and therefore phenylephrine (0.1 mg/min)
was started. The ECG obtained prior to the administra-
tion of phenylepherine showed pronounced ST segment
elevation (Figure 1) in the inferior leads, and an emergent
cardiology consult was obtained. Because the patient
remained unstable he received aspirin and started on
heparin, but no further invasive tests or procedures were
obtained at that time. His troponin obtained prior to
NAC infusion was 0.012 ng/ml and rose to 658 ng/ml
over the next 10 h. An echocardiogram obtained 2 h
after the initial EKG obtained showed global severe hypo-
kinesis with an ejection fraction of less than 20%. He died
approximately 17 h after the initiation of the intravenous
NAC loading dose. On further review, a compounding
error was discovered that had resulted in an initial dose
of 126,000 mg, which was ten-fold greater than the
appropriate loading dose for his weight.
Discussion
This case demonstrates potential difficulties with intrave-
nous NAC as demonstrated by an anaphylactoid reaction.
In addition, this case highlights the potential problems of
compounding intravenous NAC and demonstrates the
dose-dependent nature of the anaphylactoid reaction.
Anaphylactic and anaphylactoid reactions are similar
because of the massive release of histamine resulting in
hypotension, bronchospasm, pruritus, angioedema, and
rash. Anaphylactic reactions are an antibody-mediated
mast cell degranulation, which require prior sensitization
and production of the IgE antibody. In contrast, anaphy-
lactoid reactions are non-immunogenic and thus do not
require previous sensitization. Given the lack of tryptase
elevations, non-mast cell sources of histamine likely play
an important role in anaphylactoid reactions [4]. It was
the recognition of anaphylactoid reactions associated with
the intravenous formulation of NAC that precipitated an
infusion change in the packet insert, lengthening the infu-
sion time from 15 min to 60 min for the loading dose.
Risk factors for anaphylactoid reactions include atopy,
asthma, drug allergy, and low plasma acetaminophen levels,
with our patient having the latter [5]. Asthma is one of the
better-described risk factors with previous reports of severe
anaphylactoid reactions and respiratory distress following
intravenous NAC [6]. As for the cardiac manifestations
noted in this report, only two other cases reported ECG
changes with intravenous NAC. One involved ST depres-
sion and T wave inversion, which temporally resolved with
antihistamine administration [7]. The other report docu-
ments asystole, which responded to precordial thump and
intramuscular epinephrine [8]. The current report is
unique in the myocardial ischemia associated with intrave-
nous NAC, especially given his only known risk factor for
coronary artery disease was smoking.
Many controversies still exist concerning which formu-
lation is more appropriate. Oral administration is thought
to improve drug efficacy given its immediate delivery to
the liver and the first-pass effect. However, oral formula-
tions have the disadvantage of potential poor tolerance
and adherence given the nausea and vomiting associated
with administration [9]. In comparison, intravenous for-
mulations have more serious side effects, greater poten-
tial for compounding errors, and have been associated
with hyponatremia in the pediatric population [10]. Sev-
eral severe complications from intravenous NAC have
been reported, including several fatalities, one in associa-
tion with asthma [11]. In addition, adverse drug reactions
were associated with compounding errors and higher
rates of infusion [3].
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three major categories of systemic calculation, mixing, and
measuring errors. These errors with NAC are well
described, with systemic calculation errors occurring in
5% of cases, mixing errors in 9%, and measuring errors in
3% [12]. Reports of errors have been reported to be as
high as 33% of patients receiving intravenous NAC, with
18.6% having a delay or interruption in therapy for greater
than 1 h [13]. Smaller delays in therapy may cause greater
elevation in transaminases, increased length of stay, or
more serious sequelae. One patient had a delay in her
therapy secondary to an anaphylactoid reaction, which
may have contributed to her hepatic failure, as the patient
ultimately received an orthotopic liver transplant [14].
In an attempt to decrease NAC medication errors, some
advocate for a one-bag method as opposed to a three-bag
method. The three-bag method mixes a separate bag for
each dose during the FDA-approved intravenous NAC
protocol. This requires three different volumes and three
different concentrations. The alternative one-bag method
reduces the likelihood of compounding errors and also
reduces delays in administration because nursing staff is
not waiting for the pharmacy to deliver the second and
third bags. However, this method does require the nursing
staff to change the infusion rates, which does provide
another potential source for an infusion error.
Previously, both 15-min and 1-h infusions of the load-
ing dose have been used. Both protocols are equally
effective for acetaminophen poisoning, but given the
dose-dependent relationship of anaphylactoid reactions,
1-h infusions attempt to limit serious reactions. In addi-
tion, some have suggested a ceiling weight of 110 kg for
obese patients given the volume of distribution, which
also reduces the dose received [15]. In pediatric patients,
hyponatremia can complicate the intravenous adminis-
tration given the free water delivery associated with the
treatment protocol [10].
Conclusion
As serious complications with intravenous NAC con-
tinue to develop, the clinician must consider the most
appropriate route for administration. To date, studies
comparing the efficacy and risks of intravenous versus
oral NAC have not been completed. Oral NAC can be
given through a nasogastric tube for patients that cannot
tolerate the oral formulation, but complications of
aspiration need to be considered. There is always a
potential complication with any therapy; however, clini-
cians must weigh the risks and magnitude of complica-
tions for each individual patient.
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Figure 1 Initial ECG showing pronounced ST segment elevation in the inferior leads
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